Erratum: Analysis of the impact of PAPP-A, free β-hCG and nuchal translucency thickness on the advanced first trimester screening (Archives of Gynecology and Obstetrics (2013) 287 (413-420) DOI: 10.1007/s00404-012-2585-y);Analysis of the impact of PAPP-A, free β-hCG and nuchal translucency thickness on the advanced first trimester screening

Archives of Gynecology and Obstetrics

Volumn 287, Issue 3, 2013, Pages 413-420

  Berktold, L ^a   V Kaisenberg, C ^b   Hillemanns, P ^b   Vaske, B ^b   Schmidt, P ^b  

^a not available   (Germany)

^b HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

Advanced first trimester screening; Biochemistry; First trimester screening; Nuchal translucency; Trisomy 21

Indexed keywords

BIOLOGICAL MARKER; CHORIONIC GONADOTROPIN BETA SUBUNIT; PREGNANCY ASSOCIATED PLASMA PROTEIN A;

ARTICLE; CONTROLLED STUDY; DIAGNOSTIC VALUE; FALSE POSITIVE RESULT; FETUS; FIRST TRIMESTER PREGNANCY; HUMAN; MAJOR CLINICAL STUDY; MATERNAL SERUM SCREENING TEST; MEDICAL PARAMETERS; NUCHAL TRANSLUCENCY THICKNESS; PREDICTIVE VALUE; PROTEIN DETERMINATION; PROTEIN LOCALIZATION; RETROSPECTIVE STUDY; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; TRISOMY 13; TRISOMY 18; TRISOMY 21;

EID: 84878371521     PISSN: 09320067     EISSN: 14320711     Source Type: Journal    
DOI: 10.1007/s00404-013-2907-8     Document Type: Erratum

References (58)

1. Shuttleworth G (1909) Mongolian imbecility. Br Med J:661-665
2. Snijders RJ, Sundberg K, Holzgreve W, Henry G, Nicolaides KH (1999) Maternal age-and gestation-specific risk for trisomy 21. Ultrasound Obstet Gynecol 13(3):167-170
3. Nicolaides KH, Sebire N, Snijders R (1999) Nackentransparenz und Chromosomenanomalien. In: Nicolaides KH (ed) Die Ultraschalluntersuchung in der 11-14. Schwangerschaftswoche. Diagnostik fetaler Fehlbildungen. Parthenon Publishing, New York, 3-73
4. v. Kaisenberg C, Nicolaides KH, Jonat W, Brand-Saberi B (1999) Pathophysiologie und Gendosiseffekte bei chromosomal aneuploiden Feten mit erhöhtem Messwert für "nuchal translucency". Gynäkologe 32:193-199
5. Pajkrt E, de Graaf IM, Mol BW, van Lith JM, Bleker OP, Bilardo CM (1998) Weekly nuchal translucency measurements in normal fetuses. Obstet Gynecol 91(2):208-211
6. Braithwaite JM, Morris RW, Economides DL (1996) Nuchal translucency measurements: frequency distribution and changes with gestation in a general population. Br J Obstet Gynecol 103(12):1201-1204
7. Nicolaides KH, Azar G, Snijders R, Gosden C (1992) Fetal nuchal oedema: associated malformations and chromosomal defects. Fetal Diagn Ther 7:123-131
8. Nicolaides KH, Snijders RJM, Cuckle HS. (1998); Correct estimation of parameters for ultrasound nuchal translucency screening. Prenat. Diagn 18:519-521
9. Szabo J, Gellen J (1990) Nuchal fluid accumulation in trisomy-21 detected by vaginosonography in first trimester. Lancet 336(8726):1133
10. Nicolaides KH, Brizot ML, Snijders RJ (1994) Fetal nuchal translucency: ultrasound screening for fetal trisomy in the first trimester of pregnancy. Br J Obstet Gynecol 101(9):782-786
11. Ville Y, Lalondrelle C, Doumerc S et al (1992) First-trimester diagnosis of nuchal anomalies: significance and fetal outcome. Ultrasound Obstet Gynecol 2(5):314-316
12. Nicolaides KH, Azar G, Byrne D, Mansur C, Marks K (1992) Fetal nuchal translucency: ultrasound screening for chromosomal defects in first trimester of pregnancy. Br Med J 304(6831):867-869
13. Pandya PP, Brizot ML, Kuhn P, Snijders RJ, Nicolaides KH (1994) First-trimester fetal nuchal translucency thickness and risk for trisomies. Obstet Gynecol 84(3):420-423
14. Pandya PP, Snijders RJ, Johnson SP, De Lourdes Brizot M, Nicolaides KH (1995) Screening for fetal trisomies by maternal age and fetal nuchal translucency thickness at 10 to 14 weeks of gestation. Br J Obstet Gynecol 102(12):957-962
15. Spencer K, Nicolaides KH (2002) A first trimester trisomy 13/18 risk algorithm combining fetal translucency thickness, maternal serum, free β-hCG and PAPP-A. Prenat Diagn 22:877-879
16. Haddow J, Palomaki G, Knight G, Williams J, Miller W, Johnson A (1998); Screening of maternal serum for fetal Down's syndrome in the first trimester N Engl J Med 14:995-1061
17. Newby D, Aitken D, Crossley J, Howatson A, Macri J, Connor M (1997)Biochemical markers of trisomy 21 and the pathophysiology of Down's syndrome pregnancies. Prenat Diagn 17(10):941-951
18. Macri JN, Spencer K, Aitken D et al (1993) First-trimester free beta hCG screening for Down syndrome. Prenat Diagn 13(7):557-562
19. Brambati B, Macintosh MC, Teisner B et al (1993) Low maternal serum levels of pregnancy associated plasma protein A (PAPP-A) in the first trimester in association with abnormal fetal karyotype. Br J Obstet Gynecol 100(4):324-326
20. Brambati B, Tului L, Bonacchi I, Shrimanker K, Suzuki Y, Grudzinskas JG (1994) Serum PAPP-A and free beta-hCG are first-trimester screening markers for Down syndrome. Prenat Diagn 14(11):1043-1047
21. Bogart M, Pandian M (1987) Jones O. Abnormal maternal serum chorionic gonadotropin levels in pregnancies with fetal chromosome abnormalities Prenat Diagn 7:623-630
22. Wald NJ, Cuckle HS, Densem JW et al (1988) Maternal serum screening for Down's syndrome in early pregnancy. Br Med J 297(6653):883-887
23. Snijders RJ, Noble P, Sebire N, Souka A, Nicolaides KH (1988); UK multicentre project on assessment of risk of trisomy 21 by maternal age and fetal nuchal-translucency thickness at 10-14 weeks of gestation. Fetal Medicine Foundation First Trimester Screening Group. Lancet 352(9125):343-346
24. Bischof P, Amaudruz M, Weil-Franck C et al (1984) The disappearance rate of pregnancy associated plasma protein-A (PAPP-A) after the end of normal and abnormal pregnancies. Arch Gynecol Obstet 236:93-98
25. Berry E, Aitken D, Crossley J, Macri J, Connor J, Screening for Down's syndrome: changes in marker levels and detection rates between first and second trimesters. Br J Obstet Gynecol 104:811-817
26. Fialova L, Malbohan IM (2002) Pregnancy-associated plasma protein A: theoretical and clinical aspects. Bratisl Lek Listy 1036:194-205
27. Spencer K, Ong C, Skentou H, Liao AW, Nicolaides KH (2000); Screening for trisomy 13 by fetal nuchal translucency and maternal serum free β-hCG and PAPP-A at 10-14 weeks of gestation. Prenat Diagn. 20:411-416
28. Tul N, Spencer K, Noble P, Chan C, Nicolaides KH (1999); Screening for Trisomy 18 by Fetal Nuchal Translucency and Maternal Serum Free β-hCG and PAPP-A at 10-14 Weeks of Gestation. Prenat. Diagn 19:1035-1042
29. Spencer K, Souter V, Tul N, Snijders RJM, Nicolaides KH (1999) Screening program for trisomy 21 at 10/14 weeks using fetal nuchal translucency, maternal serum free β-human chorionic gonadotropin an pregnancy-associated plasma protein-A. Ultrasound Obstet Gynecol 13:231-237
30. Cuckle HS, van Lith JM (1999) Appropriate biochemical parameters in first-trimester screening for Down syndrome. Prenat Diagn 19(6):505-512
31. Wald NJ, Hackshaw AK (1997) Combining ultrasound and biochemistry in first-trimester screening for Down's syndrome. Prenat Diagn 17(9):821-829
32. Braunstein GD, Rasor J, Adler D, Danzer H, Wade ME (1976) Serum human chorionic gonadotropin levels throughout normal pregnancy. Am J Obstet Gynecol 126:678-681
33. Spencer K (1991) Evaluation of an assay of the free β-Subunit of Choriongonadotropin and its potential value in screening for Down's syndrome. Clin Chem 37(6):809-814
34. Krampl E, Wertaschnigg D, Husslein P (2002) Down-Syndrom-Screening im ersten Trimenon. Geburtsh Frauenheilk 62(9):843-848
35. Schmidt P, Hörmansdörfer C, Pruggmayer M, Schütte C, Neumann A, Gerritzen A, Vaske B, Hillemanns P, Scharf A (2008) Improved test performance for prenatal aneuploidy screening by the novel 'Advanced First trimester Screening' algorithm - a multicenter study of 10,017 pregnancies. J Clin Ultrasound 36(7):397-402
36. Schmidt P, Pruggmayer M, Steinborn A, Schippert C, Staboulidou I, Hillemanns P (2007) Are nuchal translucency, pregnancy associated plasma protein-A or free-beta-human chorionic gonadotropin depending on maternal age? A multicenter study of 8,116 pregnancies. Arch Gynecol Obstet 276(3):259-262
37. Scharf A, Schmidt P, Seppelt M, Maul H, Wüstemann M, Sohn C. (2003); Vergleich der Risikokalkulation für Trisomie 21 nach Nicolaides mit einer neu entwickelten Software: Retrospektive Analyse an 744 Fällen. Geburtsh Frauenheilk. Vol 63:148-152
38. Bindra R, Heath V, Liao A, Spencer K, Nicolaides KH (2002) One-stop clinic for assessment of risk for trisomy 21 at 11-14 weeks: a prospective study of 15 030 pregnancies. Ultrasound Obstet Gynecol 20(3):219-225
39. Schmidt P, Staboulidou I, Soergel P, Wustemann M, Hillemanns P, Scharf A (2007) Comparison of Nicolaides' risk evaluation for Down's syndrome with a novel software: an analysis of 1,463 cases. Arch Gynecol Obstet 275(6):469-474
40. Schmidt P, Scharf A. (2006); Advanced First trimester Screening - A critical review of the fundamental studies and suggestions for improvement. Geburtsh Frauenheilk 67(S1):183
41. Hörmansdörfer C, Schmidt P, Scharf A, Hillemanns P (2007) Excluding Maternal Background Risk in First Trimester Screening - Analysis of a Novel Test Strategy. Z Geburtshilfe Neonatol 211:107-174
42. von Kaisenberg CS, Gasiorek-Wiens A, Bielicki M, Bahlmann F, Meyberg H, Kossakiewicz A, Pruggmayer M, Kamin G, Fritzer E, Harris C, Arnold N (2002) Screening for trisomy 21 by maternal age, fetal nuchal translucency and maternal serum biochemistry at 11-14 weeks: a German multicenter study. J Matern Fetal Neonatal Med 12(2):89-94
43. Wapner R, Thom E, Simpson JL, Pergament E, Silver R, Filkins K, Platt L, Mahoney M, Johnson A, Hogge WA, Wilson RD, Mohide P, Hershey D, Krantz D, Zachary J, Snijders R, Greene N, Sabbagha R, MacGregor S, Hill L, Gagnon A, Hallahan T, Jackson L (2003) First-Trimester Screening for Trisomy-21 and 18. N Engl J Med 349:1405-1413
44. Nicolaides KH, Spencer K, Avgidou K, Faiola S, Falcon O (2005) Multicenter study of first-trimester screening for trisomy 21 in 75 821 pregnancies: results and estimation of the potential impact of individual risk-orientated two-stage first-trimester screening. Ultrasound Obstet Gynecol 25(3):221-226
45. Wojdemann KR, Shalmi AC, Christiansen M et al (2005) Improved first-trimester Down syndrome screening performance by lowering the false-positive rate: a prospective study of 9941 low-risk women. Ultrasound Obstet Gynecol 25:227-233
46. Schmidt P, Rom J, Maul H, Vaske B, Hillemanns P, Scharf A (2007) Advanced first trimester screening (AFS): an improved test strategy for the individual risk assessment of fetal aneuploidies and malformations. Arch Gynecol Obstet 276(2):159-166
47. Hörmansdörfer C, Schmidt P, Hillemanns P, Scharf A (2007) The prenatal detection of trisomy 13, 18, and 21: comparison of the advanced first trimester screening (AFS) with the first trimester screening according to Nicolaides Z. Geburtshilfe Neonatol 211(6):243-249
48. Schmidt P, Staboulidou I, Maul H, Beier P, Hillemanns P, Sohn C, Scharf A (2006) Advanced First trimester Screening (AFS)-Eine hochsignifikante Verbesserung der klassischen NT-Messung. Geburtsh Frauenheilk. 67:183
49. Nicolaides KH, Heath V, Cicero S (2002) Increased fetal nuchal translucency at 11-14 weeks. Prenat Diagn 22:308-315
50. Herman A, Maymon R, Dreazen E, Caspi E, Bukovsky I, Weinraub Z (1998) Nuchal translucency audit: a novel image-scoring method. Ultrasound Obstet Gynecol 12(6):398-403
51. Merz E (2002) Certified sonographic screening and certified biochemical test in early pregnancy. Ultraschall Med 23(3):161-162
52. Tabor A, Philip J, Madsen M, Bang J, Obel EB, Norgaard-Pedersen B (1986) Randomised controlled trial of genetic amniocentesis in 4606 low-risk women. Lancet 1(8493):1287-1293
53. Benz R, Muller U, Krahner-Pilat M, Wagner-Geuder S, Terinde R (1993) Serum-Screening auf Down-Syndrom bei Frauen unter 35 Jahren mit einem altersunabhängigen Index. Z Geburtshilfe Perinatol 197(5):205-208
54. Nicolaides KH, Brizot ML, Patel F, Snijders RJM (1994) Comparison of chorionic villus sampling and amniocentesis for fetal karyotyping at 10-13 weeks gestation. Lancet 344(8920):435-459
55. Sundberg K, Bang J, Smidt-Jensen S (1997) Randomised study of risk of fetal loss related to early amniocentesis versus chorionic villus sampling. Lancet 350:697-703
56. Seeds JW (2004) Diagnostic mid trimester amniocentesis: how safe? Am J Obstet Gynecol 191(2):607-615
57. Eddleman KA, Malone FD, Sullivan L, Dukes K, Berkowitz RL, Kharbutli Y et al (2006) Pregnancy loss rates after midtrimester amniocentesis. Obstet Gynecol 108(5):1067-1072
58. Steele MW, Breg WR Jr (1966) Chromosome analysis of human amniotic-fluid cells. Lancet 1(7434):383-385